Anixa Biosciences (ANIX) Stock Price, Quote, News & History | Benzinga

SPY767.15−1.40%QQQ722.10−2.89%BTC/USD81,627.00+0.07%DIA515.55−0.13%GLD376.92−1.24%TLT79.02+0.83%

Anixa Biosciences Inc (ANIX) Stock Price, Quote, News & History

ANIXNASDAQ

Trade with Public

Trade with Public

$2.65

-0.015-0.56%

Last update: Oct 14, 3:59 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$2.75

Close

$2.66

Volume / Avg.

223.45K / 300.44K

Day Range

$2.66 - $2.67

52 Wk Range

2.32 - 5.46

Market Cap

$98.73M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

-

Short Interest

4.1%

Days to Cover

3.69

Recent Anixa Biosciences Inc News

EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues

Anixa Biosciences shares new data from its ovarian cancer trial, showing patients lived longer than expected with no serious safety concerns, as regulators approved a major dose increase.

Vandana Singh

Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why

Anixa Biosciences shares surged in after-hours trading after presenting clinical trial data for its investigational breast cancer vaccine.

Mohd Haider

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

Anixa secures USPTO patent for its breast cancer vaccine using α-lactalbumin, enhancing its IP portfolio and expanding future immunotherapy options.

Vandana Singh

EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned.

Vandana Singh

EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-7.38M

Investing Cash Flow (TTM)

2.06M

Financing Cash Flow (TTM)

5.22M

Free Cash Flow (TTM)

-7.38M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-97.00K

Analyst Trends and Forecast

1

Jun

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$78.78M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

6.39

Earnings Yield % (TTM)

-12.03%

Earnings Yield % (FWD)

-12.41%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.42

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$1.40M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-